These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33171359)

  • 1. Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer.
    Parody-Rúa E; Guevara-Cuellar CA
    Value Health Reg Issues; 2020 Dec; 23():93-98. PubMed ID: 33171359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trial-Based Cost-Effectiveness Analysis of Bevacizumab and Chemotherapy Versus Chemotherapy Alone for Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
    Li X; Li W; Hou L
    Value Health Reg Issues; 2019 May; 18():1-7. PubMed ID: 30412913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
    Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
    Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer.
    Lin S; Luo S; Zhong L; Lai S; Zeng D; Rao X; Huang P; Weng X
    Int J Clin Pharm; 2020 Aug; 42(4):1175-1183. PubMed ID: 32524512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B; Ramsey S
    Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.
    Zheng H; Xie L; Zhan M; Wen F; Xu T; Li Q
    Clin Transl Oncol; 2018 Mar; 20(3):286-293. PubMed ID: 28785913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 13. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review.
    Chouaïd C; Crequit P; Borget I; Vergnenegre A
    Clinicoecon Outcomes Res; 2015; 7():9-15. PubMed ID: 25548525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
    Mehta DA; Hay JW
    Gynecol Oncol; 2014 Mar; 132(3):677-83. PubMed ID: 24463160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
    Permsuwan U; Thongprasert S; Sirichanchuen B
    Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
    Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.